4 citations
,
March 2024 in “Journal of the American Academy of Dermatology” Spironolactone for skin issues rarely causes low blood pressure.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
26 citations
,
June 1983 in “Journal of Hypertension” Minoxidil lowers blood pressure more effectively but has more side effects, so try hydralazine first.
A new topical treatment for hair loss is effective and safe with faster results.
13 citations
,
February 2022 in “JAMA Dermatology” Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.
September 2022 in “Journal of The American Academy of Dermatology” Monitoring potassium levels is important for women taking spironolactone.
A new topical treatment for hair loss is effective and safe with faster results.
A new topical treatment for hair loss is effective and safe with faster results.
A new topical treatment for hair loss is effective and safe with faster results.
A new topical treatment for hair loss is effective and safe with faster results.
A new topical treatment for hair loss is effective and safe with faster results.
129 citations
,
January 2004 in “Journal of medicinal chemistry” Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.
11 citations
,
January 1980 in “Southern Medical Journal” Minoxidil effectively treats severe hypertension but has notable side effects.
A new topical treatment for hair loss is effective and safe with faster results.
A new topical treatment for hair loss is effective and safe with faster results.
A new topical treatment for hair loss is effective and safe with faster results.
119 citations
,
October 1992 in “Fundamental & Clinical Pharmacology” Potassium channel openers could help treat cardiovascular diseases and asthma but require better targeting to specific tissues for effective use.
18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
50 citations
,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
January 2022 in “Asian journal of Current Research in Clinical Cancer” Some dibenzo compounds might help treat cancer with fewer side effects.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
1 citations
,
October 2020 in “Current Drug Discovery Technologies” The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
14 citations
,
November 2014 in “European journal of medicinal chemistry” Researchers found new potential treatments for conditions related to the androgen receptor, like male hormonal contraception, by testing thousands of compounds.
10 citations
,
December 2009 in “Journal of the American Geriatrics Society” Older adults using diuretics should manage water intake carefully to avoid low sodium levels.
January 1993 in “Проблемы Эндокринологии” Spironolactone effectively reduces symptoms of hyperandrogenism but has some side effects.
April 2023 in “Medicina Clínica (english Edition)” 18 citations
,
June 2016 in “PeerJ” Testosterone increases certain kidney protein levels, potentially raising blood pressure.
July 2026 in “Journal of Medicinal Chemistry” A new drug strategy improves hair loss treatment with better results and safety.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.